drugset / Trial / NCT05868382

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382

Phase 2 Completed 270 enrolled ModernaTX, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.

Timeline

Start
2023-05-15
Primary completion
2023-12-19
Completion
2023-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent influenza vaccine Vaccine Intramuscular
Subject mRNA-1010.4 Unknown Intramuscular
Subject mRNA-1010.6 Unknown Intramuscular

Indications